Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile-associated Diarrhea (CDAD)
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Trial Timeline
Jan 9, 2015 → Mar 7, 2018
NCT ID
NCT02218372About Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules is a phase 3 stage product being developed by Astellas Pharma for Clostridium Difficile-associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT02218372. Target conditions include Clostridium Difficile-associated Diarrhea (CDAD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02218372 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Difficile-associated Diarrhea (CDAD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fidaxomicin + Vancomycin + Placebo | Astellas Pharma | Approved | 85 |
| Fidaxomicin + Treatment for CDI other than fidaxomicin Type | Astellas Pharma | Pre-clinical | 23 |
| OPT-80 + vancomycin | Astellas Pharma | Phase 3 | 77 |
| Fidaxomicin + Vancomycin | Astellas Pharma | Approved | 85 |
| Fidaxomicin + Vancomycin | Merck | Approved | 85 |
| fidaxomicin + Placebo | Merck | Phase 3 | 77 |
| Surotomycin + Placebo | Merck | Phase 1 | 33 |
| CB-183,315 + Placebo + Vancomycin | Merck | Phase 2 | 52 |
| Surotomycin + Placebo | Merck | Phase 1 | 33 |
| MK-6072 + MK-3415A + Placebo + SOC | Merck | Phase 3 | 77 |
| Vancomycin + Fidaxomicin | Merck | Approved | 85 |
| Fidaxomicin | Merck | Pre-clinical | 23 |
| Bezlotoxumab + Standard CDI treatment | Merck | Pre-clinical | 23 |
| MK-3415 + MK-6072 + MK-3415A + Placebo + SOC | Merck | Phase 3 | 77 |
| Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin | Merck | Phase 3 | 77 |
| bezlotoxumab + Vancomycin Oral | Merck | Approved | 85 |
| Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD) | Merck | Phase 3 | 77 |
| Bezlotoxumab Injection [Zinplava] | Merck | Pre-clinical | 23 |
| PAR-101/OPT-80 + Vancomycin | Merck | Phase 3 | 77 |
| fidaxomicin | Merck | Phase 2 | 52 |